- Home
- AVBH vs ABEO Comparison
AVBH vs ABEO Comparison
Compare AVBH & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVBH | ABEO |
|---|---|---|
| Founded | 2003 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.6M | 399.5M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AVBH | ABEO |
|---|---|---|
| Price | $30.94 | $5.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $38.80 | $18.88 |
| AVG Volume (30 Days) | 51.3K | ★ 1.3M |
| Earning Date | 10-22-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ 1.55 | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $24.18 | $804.33 |
| Revenue Next Year | $10.55 | $119.68 |
| P/E Ratio | $20.16 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $24.03 | $4.00 |
| 52 Week High | $34.18 | $7.65 |
Technical Indicators
Market Signals| Indicator | AVBH | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 35.55 |
| Support Level | $30.18 | $4.94 |
| Resistance Level | $31.10 | $5.46 |
| Average True Range (ATR) | 0.46 | 0.21 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 10.26 | 11.39 |
Price Performance
Historical ComparisonAbout AVBH Avidbank Holdings Inc.
Avidbank Holdings Inc is a full-service commercial bank. It offers various services such as commercial and industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, real estate construction, and commercial real estate lending.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.